Aisling Capital
Company: Aisling Capital
Description: Aisling Capital is a forward-thinking venture capital and private equity firm that anticipates significant transformations in the healthcare landscape over the coming decade. The firm firmly believes that this revolution will be largely driven by innovative therapeutics emerging from advancements in biotechnology. With the successful completion of the human genome project, scientists have gained unprecedented insights into the underlying causes of human diseases.
These insights, coupled with two decades of substantial progress within the biotechnology sector, are catalyzing the rapid development of novel strategies aimed at the diagnosis, prevention, and treatment of life-threatening illnesses. As a result, there is an increasing need for capital investment to facilitate the final stages of development and commercialization for new therapeutics.
Aisling Capital is dedicated to supporting leading global healthcare companies that are at the forefront of harnessing these technical and medical breakthroughs. The firm is committed to fostering the commercialization of innovative healthcare products that have the potential to transform patient care and improve health outcomes worldwide. Through its strategic investments, Aisling Capital aims to play a pivotal role in the advancement of healthcare solutions that address critical needs in society.
Industry: Venture Capital and Private Equity
Domain: http://www.aislingcapital.com/
Founded: 2000
Location: New York, NY
Address: 888 7th Avenue, 12th Floor, New York, NY 10106, US
Size: 11-50 employees
Direct Contacts
Name: Jan Hoerrner
Title: Director of Investor Relations & Marketing
Email: Direct Email
Company: Aisling Capital
Phone: (212)-651-6380
Industry: Venture Capital and Private Equity
Location: New York, New York